Table 4.
Initial laboratory findings for survivor and non-survivor patients (N=362)
| Laboratory findings | Cut-point | Missing data | Total* | Survivor N=280 (77.3%) | Non-Survivor N=82 (22.7%) | P-Value |
|---|---|---|---|---|---|---|
| D-dimer | >1 mg/L | 124 (34.3%) | 138 (58.0%) | 86 (48.3%) | 52 (86.7%) | <0.001 |
| CRP | >100 mg/L | 46 (12.7%) | 170 (53.8%) | 106 (45.1%) | 64 (79.0%) | <0.001 |
| PT | >12 sec | 71 (19.6%) | 244 (83.8%) | 172 (81.1%) | 72 (91.1%) | 0.039 |
| Troponin | Positive | 222 (61.3%) | 9 (6.4%) | 4 (4.4%) | 5 (10.2%) | 0.277 |
| Ferritin | >500 ng/ml | 314 (86.7%) | 12 (25.0%) | 9 (20.5%) | 3 (75.0%) | 0.043 |
| WBC | >10 ×103/μL | 12 (3.3%) | 129 (36.9%) | 76 (28.4%) | 53 (64.6%) | <0.001 |
| Neutrophil count | > 7 X109/L | 24 (6.6%) | 155 (45.9%) | 90 (34.9%) | 65 (81.3%) | <0.001 |
| ALT | >53 IU/L | 31 (8.6%) | 85 (25.7%) | 60 (24.0%) | 25 (30.9%) | 0.219 |
| AST | >47 IU/L | 34 (9.4%) | 126 (38.4%) | 77 (31.2%) | 49 (60.5%) | <0.001 |
| Creatinine | > 104 µmol/L | 17 (4.7%) | 92 (26.7%) | 59 (22.4%) | 33 (40.2%) | 0.001 |
| BUN | >8.9 mmol/L | 30 (8.3%) | 141 (42.5%) | 77 (30.8%) | 64 (78.0%) | <0.001 |
| Procalcitonin | > 2.0 ng/mL | 333 (92.0%) | 4 (13.8%) | 3 (15.0%) | 1 (11.1%) | 1.00 |
| Lymphocyte count | <0.8 x109/L | 23 (6.4%) | 177 (52.2%) | 113 (44.0%) | 64 (78.0%) | <0.001 |
| Platelet count | <140 × 103/μL | 16 (4.4%) | 64 (18.5%) | 46 (17.4%) | 18 (22.0%) | 0.356 |
| Albumin | < 3.5 g/dL | 213 (58.8%) | 89 (59.7%) | 44 (44.0%) | 45 (91.8%) | <0.001 |
| Hemoglobin | <14 g/dL | 12 (3.3%) | 240 (68.6%) | 178 (66.4%) | 62 (75.6%) | 0.117 |
*
Represents all patients with reported laboratory parameter and achieved the cut-point. PT= prothrombin time. WBC= White blood cells. ALT= alanine aminotransferase. AST= aspartate transferase. BUN= blood urea nitrogen.